Isoray, Inc.
Isoray, Inc. (ISR) Stock Competitors & Peer Comparison
See (ISR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ISR | $0.38 | +0.03% | 0 | N/A | N/A | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ISRG | $438.10 | -0.39% | 155.2B | 53.17 | $8.24 | N/A |
| ABT | $87.41 | -0.41% | 152.3B | 24.48 | $3.57 | +2.79% |
| SYK | $316.48 | +0.95% | 121.3B | 36.63 | $8.64 | +1.09% |
| MDT | $78.60 | +0.58% | 100.9B | 21.96 | $3.58 | +3.61% |
| BSX | $57.78 | +1.10% | 85.9B | 24.18 | $2.39 | N/A |
| BRKRP | $349.15 | +1.94% | 53.1B | N/A | N/A | +0.44% |
| EW | $85.78 | +3.10% | 49.4B | 46.37 | $1.85 | N/A |
| RMD | $208.05 | -0.45% | 30.2B | 20.08 | $10.36 | +1.15% |
Stock Comparison
ISR vs BSX-PA Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ISR is priced at $0.38, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ISR's ROE is -0.42%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ISR is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BSX-PA's competition here
ISR vs ISRG Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ISRG has a market cap of 155.2B. Regarding current trading prices, ISR is priced at $0.38, while ISRG trades at $438.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ISRG's P/E ratio is 53.17. In terms of profitability, ISR's ROE is -0.42%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ISR is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ISRG's competition here
ISR vs ABT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ABT has a market cap of 152.3B. Regarding current trading prices, ISR is priced at $0.38, while ABT trades at $87.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 24.48. In terms of profitability, ISR's ROE is -0.42%, compared to ABT's ROE of +0.12%. Regarding short-term risk, ISR is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ABT's competition here
ISR vs SYK Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SYK has a market cap of 121.3B. Regarding current trading prices, ISR is priced at $0.38, while SYK trades at $316.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SYK's P/E ratio is 36.63. In terms of profitability, ISR's ROE is -0.42%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ISR is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SYK's competition here
ISR vs MDT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, MDT has a market cap of 100.9B. Regarding current trading prices, ISR is priced at $0.38, while MDT trades at $78.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas MDT's P/E ratio is 21.96. In terms of profitability, ISR's ROE is -0.42%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ISR is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check MDT's competition here
ISR vs BSX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BSX has a market cap of 85.9B. Regarding current trading prices, ISR is priced at $0.38, while BSX trades at $57.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BSX's P/E ratio is 24.18. In terms of profitability, ISR's ROE is -0.42%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ISR is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BSX's competition here
ISR vs BRKRP Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BRKRP has a market cap of 53.1B. Regarding current trading prices, ISR is priced at $0.38, while BRKRP trades at $349.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BRKRP's P/E ratio is N/A. In terms of profitability, ISR's ROE is -0.42%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, ISR is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BRKRP's competition here
ISR vs EW Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, ISR is priced at $0.38, while EW trades at $85.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas EW's P/E ratio is 46.37. In terms of profitability, ISR's ROE is -0.42%, compared to EW's ROE of +0.11%. Regarding short-term risk, ISR is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check EW's competition here
ISR vs RMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, RMD has a market cap of 30.2B. Regarding current trading prices, ISR is priced at $0.38, while RMD trades at $208.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas RMD's P/E ratio is 20.08. In terms of profitability, ISR's ROE is -0.42%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ISR is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check RMD's competition here
ISR vs DXCM Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, DXCM has a market cap of 27.8B. Regarding current trading prices, ISR is priced at $0.38, while DXCM trades at $72.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas DXCM's P/E ratio is 30.94. In terms of profitability, ISR's ROE is -0.42%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, ISR is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check DXCM's competition here
ISR vs PHG Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PHG has a market cap of 25.7B. Regarding current trading prices, ISR is priced at $0.38, while PHG trades at $26.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PHG's P/E ratio is 23.23. In terms of profitability, ISR's ROE is -0.42%, compared to PHG's ROE of +0.09%. Regarding short-term risk, ISR is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check PHG's competition here
ISR vs STE Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, STE has a market cap of 21.3B. Regarding current trading prices, ISR is priced at $0.38, while STE trades at $216.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas STE's P/E ratio is 27.31. In terms of profitability, ISR's ROE is -0.42%, compared to STE's ROE of +0.11%. Regarding short-term risk, ISR is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check STE's competition here
ISR vs ABMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ISR is priced at $0.38, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ISR's ROE is -0.42%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ISR is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ABMD's competition here
ISR vs ZBH Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ZBH has a market cap of 16.5B. Regarding current trading prices, ISR is priced at $0.38, while ZBH trades at $85.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ZBH's P/E ratio is 22.15. In terms of profitability, ISR's ROE is -0.42%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ISR is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ZBH's competition here
ISR vs SNN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SNN has a market cap of 13B. Regarding current trading prices, ISR is priced at $0.38, while SNN trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SNN's P/E ratio is 21.35. In terms of profitability, ISR's ROE is -0.42%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ISR is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SNN's competition here
ISR vs PEN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, ISR is priced at $0.38, while PEN trades at $328.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PEN's P/E ratio is 75.74. In terms of profitability, ISR's ROE is -0.42%, compared to PEN's ROE of +0.12%. Regarding short-term risk, ISR is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check PEN's competition here
ISR vs SWAV Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ISR is priced at $0.38, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ISR's ROE is -0.42%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ISR is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SWAV's competition here
ISR vs ALGN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ALGN has a market cap of 11.7B. Regarding current trading prices, ISR is priced at $0.38, while ALGN trades at $163.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ALGN's P/E ratio is 27.45. In terms of profitability, ISR's ROE is -0.42%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ISR is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ALGN's competition here
ISR vs GMED Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, GMED has a market cap of 11.4B. Regarding current trading prices, ISR is priced at $0.38, while GMED trades at $84.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas GMED's P/E ratio is 19.82. In terms of profitability, ISR's ROE is -0.42%, compared to GMED's ROE of +0.13%. Regarding short-term risk, ISR is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check GMED's competition here
ISR vs PODD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PODD has a market cap of 10.7B. Regarding current trading prices, ISR is priced at $0.38, while PODD trades at $154.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PODD's P/E ratio is 36.27. In terms of profitability, ISR's ROE is -0.42%, compared to PODD's ROE of +0.21%. Regarding short-term risk, ISR is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check PODD's competition here
ISR vs MASI Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ISR is priced at $0.38, while MASI trades at $178.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas MASI's P/E ratio is 44.26. In terms of profitability, ISR's ROE is -0.42%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ISR is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check MASI's competition here
ISR vs BIO Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BIO has a market cap of 7.8B. Regarding current trading prices, ISR is priced at $0.38, while BIO trades at $287.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BIO's P/E ratio is 47.88. In terms of profitability, ISR's ROE is -0.42%, compared to BIO's ROE of +0.02%. Regarding short-term risk, ISR is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BIO's competition here
ISR vs BIO-B Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BIO-B has a market cap of 7.5B. Regarding current trading prices, ISR is priced at $0.38, while BIO-B trades at $276.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BIO-B's P/E ratio is 46.10. In terms of profitability, ISR's ROE is -0.42%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, ISR is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BIO-B's competition here
ISR vs GKOS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, ISR is priced at $0.38, while GKOS trades at $120.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas GKOS's P/E ratio is -36.54. In terms of profitability, ISR's ROE is -0.42%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, ISR is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check GKOS's competition here
ISR vs BRKR Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BRKR has a market cap of 7B. Regarding current trading prices, ISR is priced at $0.38, while BRKR trades at $45.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BRKR's P/E ratio is -190.37. In terms of profitability, ISR's ROE is -0.42%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, ISR is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BRKR's competition here
ISR vs NARI Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ISR is priced at $0.38, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas NARI's P/E ratio is -59.24. In terms of profitability, ISR's ROE is -0.42%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ISR is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check NARI's competition here
ISR vs LIVN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, ISR is priced at $0.38, while LIVN trades at $73.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas LIVN's P/E ratio is 37.67. In terms of profitability, ISR's ROE is -0.42%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, ISR is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check LIVN's competition here
ISR vs IRTC Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, ISR is priced at $0.38, while IRTC trades at $116.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas IRTC's P/E ratio is -137.13. In terms of profitability, ISR's ROE is -0.42%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, ISR is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check IRTC's competition here
ISR vs AXNX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ISR is priced at $0.38, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ISR's ROE is -0.42%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ISR is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check AXNX's competition here
ISR vs ITGR Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, ISR is priced at $0.38, while ITGR trades at $89.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ITGR's P/E ratio is 22.15. In terms of profitability, ISR's ROE is -0.42%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, ISR is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ITGR's competition here
ISR vs TMDX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, ISR is priced at $0.38, while TMDX trades at $68.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas TMDX's P/E ratio is 15.77. In terms of profitability, ISR's ROE is -0.42%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, ISR is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check TMDX's competition here
ISR vs AXGN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, ISR is priced at $0.38, while AXGN trades at $40.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas AXGN's P/E ratio is -63.91. In terms of profitability, ISR's ROE is -0.42%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, ISR is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check AXGN's competition here
ISR vs ESTA Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, ISR is priced at $0.38, while ESTA trades at $72.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ESTA's P/E ratio is -49.11. In terms of profitability, ISR's ROE is -0.42%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, ISR is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ESTA's competition here
ISR vs NUVA Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ISR is priced at $0.38, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ISR's ROE is -0.42%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ISR is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check NUVA's competition here
ISR vs UFPT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, ISR is priced at $0.38, while UFPT trades at $228.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas UFPT's P/E ratio is 26.11. In terms of profitability, ISR's ROE is -0.42%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ISR is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check UFPT's competition here
ISR vs PRCT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PRCT has a market cap of 1.7B. Regarding current trading prices, ISR is priced at $0.38, while PRCT trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PRCT's P/E ratio is -15.85. In terms of profitability, ISR's ROE is -0.42%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ISR is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check PRCT's competition here
ISR vs AHCO Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, ISR is priced at $0.38, while AHCO trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas AHCO's P/E ratio is -17.71. In terms of profitability, ISR's ROE is -0.42%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ISR is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check AHCO's competition here
ISR vs ENOV Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, ISR is priced at $0.38, while ENOV trades at $24.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ENOV's P/E ratio is -1.22. In terms of profitability, ISR's ROE is -0.42%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, ISR is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ENOV's competition here
ISR vs HSKA Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ISR is priced at $0.38, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ISR's ROE is -0.42%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ISR is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check HSKA's competition here
ISR vs ATEC Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ATEC has a market cap of 1.3B. Regarding current trading prices, ISR is priced at $0.38, while ATEC trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ATEC's P/E ratio is -9.96. In terms of profitability, ISR's ROE is -0.42%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, ISR is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ATEC's competition here
ISR vs INSP Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, ISR is priced at $0.38, while INSP trades at $43.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas INSP's P/E ratio is 9.96. In terms of profitability, ISR's ROE is -0.42%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ISR is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check INSP's competition here
ISR vs IRMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ISR is priced at $0.38, while IRMD trades at $92.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas IRMD's P/E ratio is 50.33. In terms of profitability, ISR's ROE is -0.42%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ISR is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check IRMD's competition here
ISR vs IART Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, ISR is priced at $0.38, while IART trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas IART's P/E ratio is -2.33. In terms of profitability, ISR's ROE is -0.42%, compared to IART's ROE of -0.48%. Regarding short-term risk, ISR is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check IART's competition here
ISR vs BFLY Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, ISR is priced at $0.38, while BFLY trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BFLY's P/E ratio is -14.90. In terms of profitability, ISR's ROE is -0.42%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, ISR is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BFLY's competition here
ISR vs AVNS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ISR is priced at $0.38, while AVNS trades at $24.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas AVNS's P/E ratio is -15.38. In terms of profitability, ISR's ROE is -0.42%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ISR is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check AVNS's competition here
ISR vs CNMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, ISR is priced at $0.38, while CNMD trades at $37.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CNMD's P/E ratio is 21.03. In terms of profitability, ISR's ROE is -0.42%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ISR is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CNMD's competition here
ISR vs SILK Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ISR is priced at $0.38, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SILK's P/E ratio is -18.96. In terms of profitability, ISR's ROE is -0.42%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ISR is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SILK's competition here
ISR vs FNA Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ISR is priced at $0.38, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas FNA's P/E ratio is -19.83. In terms of profitability, ISR's ROE is -0.42%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ISR is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check FNA's competition here
ISR vs AORT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ISR is priced at $0.38, while AORT trades at $22.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas AORT's P/E ratio is 89.84. In terms of profitability, ISR's ROE is -0.42%, compared to AORT's ROE of +0.03%. Regarding short-term risk, ISR is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check AORT's competition here
ISR vs TNDM Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, ISR is priced at $0.38, while TNDM trades at $14.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas TNDM's P/E ratio is -10.92. In terms of profitability, ISR's ROE is -0.42%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, ISR is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check TNDM's competition here
ISR vs INMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, INMD has a market cap of 870.5M. Regarding current trading prices, ISR is priced at $0.38, while INMD trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas INMD's P/E ratio is 10.18. In terms of profitability, ISR's ROE is -0.42%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ISR is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check INMD's competition here
ISR vs CSII Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ISR is priced at $0.38, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CSII's P/E ratio is -20.83. In terms of profitability, ISR's ROE is -0.42%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ISR is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CSII's competition here
ISR vs SSII Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SSII has a market cap of 778.5M. Regarding current trading prices, ISR is priced at $0.38, while SSII trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SSII's P/E ratio is -77.80. In terms of profitability, ISR's ROE is -0.42%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ISR is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SSII's competition here
ISR vs LMRI Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, LMRI has a market cap of 768.6M. Regarding current trading prices, ISR is priced at $0.38, while LMRI trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas LMRI's P/E ratio is -20.51. In terms of profitability, ISR's ROE is -0.42%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, ISR is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check LMRI's competition here
ISR vs CRY Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ISR is priced at $0.38, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CRY's P/E ratio is 425.71. In terms of profitability, ISR's ROE is -0.42%, compared to CRY's ROE of +0.03%. Regarding short-term risk, ISR is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CRY's competition here
ISR vs CBLL Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CBLL has a market cap of 712.2M. Regarding current trading prices, ISR is priced at $0.38, while CBLL trades at $18.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CBLL's P/E ratio is -11.59. In terms of profitability, ISR's ROE is -0.42%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ISR is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CBLL's competition here
ISR vs SIBN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SIBN has a market cap of 651M. Regarding current trading prices, ISR is priced at $0.38, while SIBN trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SIBN's P/E ratio is -37.64. In terms of profitability, ISR's ROE is -0.42%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, ISR is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SIBN's competition here
ISR vs BVS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BVS has a market cap of 628.7M. Regarding current trading prices, ISR is priced at $0.38, while BVS trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BVS's P/E ratio is 22.63. In terms of profitability, ISR's ROE is -0.42%, compared to BVS's ROE of +0.16%. Regarding short-term risk, ISR is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BVS's competition here
ISR vs SRDX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ISR is priced at $0.38, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ISR's ROE is -0.42%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, ISR is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SRDX's competition here
ISR vs BWAY Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BWAY has a market cap of 592.3M. Regarding current trading prices, ISR is priced at $0.38, while BWAY trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BWAY's P/E ratio is 68.64. In terms of profitability, ISR's ROE is -0.42%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ISR is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check BWAY's competition here
ISR vs APEN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ISR is priced at $0.38, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas APEN's P/E ratio is -9.43. In terms of profitability, ISR's ROE is -0.42%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ISR is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check APEN's competition here
ISR vs NPCE Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, NPCE has a market cap of 576.9M. Regarding current trading prices, ISR is priced at $0.38, while NPCE trades at $16.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas NPCE's P/E ratio is -26.03. In terms of profitability, ISR's ROE is -0.42%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ISR is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check NPCE's competition here
ISR vs TCMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, TCMD has a market cap of 561.7M. Regarding current trading prices, ISR is priced at $0.38, while TCMD trades at $24.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas TCMD's P/E ratio is 28.62. In terms of profitability, ISR's ROE is -0.42%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ISR is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check TCMD's competition here
ISR vs CERS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CERS has a market cap of 543M. Regarding current trading prices, ISR is priced at $0.38, while CERS trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CERS's P/E ratio is -54.20. In terms of profitability, ISR's ROE is -0.42%, compared to CERS's ROE of -0.15%. Regarding short-term risk, ISR is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CERS's competition here
ISR vs ZIMV Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ISR is priced at $0.38, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ISR's ROE is -0.42%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ISR is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ZIMV's competition here
ISR vs CTKB Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CTKB has a market cap of 517.9M. Regarding current trading prices, ISR is priced at $0.38, while CTKB trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CTKB's P/E ratio is -6.91. In terms of profitability, ISR's ROE is -0.42%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, ISR is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CTKB's competition here
ISR vs KIDS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, KIDS has a market cap of 471.8M. Regarding current trading prices, ISR is priced at $0.38, while KIDS trades at $18.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas KIDS's P/E ratio is -10.93. In terms of profitability, ISR's ROE is -0.42%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ISR is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check KIDS's competition here
ISR vs OFIX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, OFIX has a market cap of 434.5M. Regarding current trading prices, ISR is priced at $0.38, while OFIX trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas OFIX's P/E ratio is -7.17. In terms of profitability, ISR's ROE is -0.42%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, ISR is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check OFIX's competition here
ISR vs VREX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, VREX has a market cap of 423.9M. Regarding current trading prices, ISR is priced at $0.38, while VREX trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas VREX's P/E ratio is -5.03. In terms of profitability, ISR's ROE is -0.42%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ISR is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check VREX's competition here
ISR vs LAB Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, LAB has a market cap of 402.1M. Regarding current trading prices, ISR is priced at $0.38, while LAB trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas LAB's P/E ratio is -7.92. In terms of profitability, ISR's ROE is -0.42%, compared to LAB's ROE of -0.21%. Regarding short-term risk, ISR is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check LAB's competition here
ISR vs DCTH Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, DCTH has a market cap of 380.4M. Regarding current trading prices, ISR is priced at $0.38, while DCTH trades at $11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas DCTH's P/E ratio is 1102.00. In terms of profitability, ISR's ROE is -0.42%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, ISR is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check DCTH's competition here
ISR vs PACB Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PACB has a market cap of 378.9M. Regarding current trading prices, ISR is priced at $0.38, while PACB trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PACB's P/E ratio is -2.98. In terms of profitability, ISR's ROE is -0.42%, compared to PACB's ROE of -4.88%. Regarding short-term risk, ISR is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check PACB's competition here
ISR vs VMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, VMD has a market cap of 370M. Regarding current trading prices, ISR is priced at $0.38, while VMD trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 26.08. In terms of profitability, ISR's ROE is -0.42%, compared to VMD's ROE of +0.11%. Regarding short-term risk, ISR is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check VMD's competition here
ISR vs AVR Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, AVR has a market cap of 353.9M. Regarding current trading prices, ISR is priced at $0.38, while AVR trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas AVR's P/E ratio is -4.33. In terms of profitability, ISR's ROE is -0.42%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ISR is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check AVR's competition here
ISR vs CLPT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CLPT has a market cap of 343.1M. Regarding current trading prices, ISR is priced at $0.38, while CLPT trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CLPT's P/E ratio is -11.44. In terms of profitability, ISR's ROE is -0.42%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, ISR is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CLPT's competition here
ISR vs ELMD Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ELMD has a market cap of 316.5M. Regarding current trading prices, ISR is priced at $0.38, while ELMD trades at $38.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ELMD's P/E ratio is 32.67. In terms of profitability, ISR's ROE is -0.42%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ISR is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ELMD's competition here
ISR vs SMLR Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ISR is priced at $0.38, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ISR's ROE is -0.42%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ISR is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SMLR's competition here
ISR vs CATX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CATX has a market cap of 307.5M. Regarding current trading prices, ISR is priced at $0.38, while CATX trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CATX's P/E ratio is -2.82. In terms of profitability, ISR's ROE is -0.42%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ISR is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CATX's competition here
ISR vs MASS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, MASS has a market cap of 275.3M. Regarding current trading prices, ISR is priced at $0.38, while MASS trades at $7.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas MASS's P/E ratio is -7.51. In terms of profitability, ISR's ROE is -0.42%, compared to MASS's ROE of -0.26%. Regarding short-term risk, ISR is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check MASS's competition here
ISR vs SGHT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SGHT has a market cap of 273.7M. Regarding current trading prices, ISR is priced at $0.38, while SGHT trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SGHT's P/E ratio is -7.19. In terms of profitability, ISR's ROE is -0.42%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, ISR is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SGHT's competition here
ISR vs SENS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SENS has a market cap of 265M. Regarding current trading prices, ISR is priced at $0.38, while SENS trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SENS's P/E ratio is -3.22. In terms of profitability, ISR's ROE is -0.42%, compared to SENS's ROE of -1.30%. Regarding short-term risk, ISR is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SENS's competition here
ISR vs RXST Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, RXST has a market cap of 251.9M. Regarding current trading prices, ISR is priced at $0.38, while RXST trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas RXST's P/E ratio is -5.38. In terms of profitability, ISR's ROE is -0.42%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ISR is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check RXST's competition here
ISR vs MGRM Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ISR is priced at $0.38, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas MGRM's P/E ratio is -11.11. In terms of profitability, ISR's ROE is -0.42%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, ISR is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check MGRM's competition here
ISR vs PMI Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PMI has a market cap of 235.6M. Regarding current trading prices, ISR is priced at $0.38, while PMI trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PMI's P/E ratio is -0.20. In terms of profitability, ISR's ROE is -0.42%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ISR is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check PMI's competition here
ISR vs NVRO Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ISR is priced at $0.38, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ISR's ROE is -0.42%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ISR is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check NVRO's competition here
ISR vs EYES Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ISR is priced at $0.38, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas EYES's P/E ratio is N/A. In terms of profitability, ISR's ROE is -0.42%, compared to EYES's ROE of -2.64%. Regarding short-term risk, ISR is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check EYES's competition here
ISR vs PROF Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, PROF has a market cap of 206.7M. Regarding current trading prices, ISR is priced at $0.38, while PROF trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas PROF's P/E ratio is -5.51. In terms of profitability, ISR's ROE is -0.42%, compared to PROF's ROE of -0.71%. Regarding short-term risk, ISR is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check PROF's competition here
ISR vs ANIK Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, ANIK has a market cap of 198M. Regarding current trading prices, ISR is priced at $0.38, while ANIK trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas ANIK's P/E ratio is -18.84. In terms of profitability, ISR's ROE is -0.42%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, ISR is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check ANIK's competition here
ISR vs BSGM Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ISR is priced at $0.38, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ISR's ROE is -0.42%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ISR is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check BSGM's competition here
ISR vs TMCI Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, TMCI has a market cap of 180.3M. Regarding current trading prices, ISR is priced at $0.38, while TMCI trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas TMCI's P/E ratio is -2.90. In terms of profitability, ISR's ROE is -0.42%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, ISR is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check TMCI's competition here
ISR vs MDGS Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ISR is priced at $0.38, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ISR's ROE is -0.42%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ISR is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ISR.Check MDGS's competition here
ISR vs INGN Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, INGN has a market cap of 173.3M. Regarding current trading prices, ISR is priced at $0.38, while INGN trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas INGN's P/E ratio is -7.03. In terms of profitability, ISR's ROE is -0.42%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ISR is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check INGN's competition here
ISR vs APYX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, APYX has a market cap of 172.9M. Regarding current trading prices, ISR is priced at $0.38, while APYX trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas APYX's P/E ratio is -18.77. In terms of profitability, ISR's ROE is -0.42%, compared to APYX's ROE of -0.91%. Regarding short-term risk, ISR is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check APYX's competition here
ISR vs QIPT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ISR is priced at $0.38, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ISR's ROE is -0.42%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ISR is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check QIPT's competition here
ISR vs CVRX Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, CVRX has a market cap of 162.1M. Regarding current trading prices, ISR is priced at $0.38, while CVRX trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas CVRX's P/E ratio is -3.04. In terms of profitability, ISR's ROE is -0.42%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, ISR is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check CVRX's competition here
ISR vs EDAP Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, EDAP has a market cap of 161.2M. Regarding current trading prices, ISR is priced at $0.38, while EDAP trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas EDAP's P/E ratio is -5.24. In terms of profitability, ISR's ROE is -0.42%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, ISR is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check EDAP's competition here
ISR vs SNWV Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, SNWV has a market cap of 143.5M. Regarding current trading prices, ISR is priced at $0.38, while SNWV trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas SNWV's P/E ratio is 17.39. In terms of profitability, ISR's ROE is -0.42%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, ISR is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check SNWV's competition here
ISR vs QTI Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, QTI has a market cap of 136.5M. Regarding current trading prices, ISR is priced at $0.38, while QTI trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas QTI's P/E ratio is -4.79. In terms of profitability, ISR's ROE is -0.42%, compared to QTI's ROE of -63.30%. Regarding short-term risk, ISR is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check QTI's competition here
ISR vs HSDT Comparison May 2026
ISR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ISR stands at 0. In comparison, HSDT has a market cap of 133.7M. Regarding current trading prices, ISR is priced at $0.38, while HSDT trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ISR currently has a P/E ratio of N/A, whereas HSDT's P/E ratio is 0.01. In terms of profitability, ISR's ROE is -0.42%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ISR is more volatile compared to HSDT. This indicates potentially higher risk in terms of short-term price fluctuations for ISR.Check HSDT's competition here